Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia

被引：0
|
作者：
Dongwoo Kang
Elizabeth Ludwig
David Jaworowicz
Hannah Huang
Jill Fiedler-Kelly
Jorge Cortes
Siddhartha Ganguly
Samer Khaled
Alwin Krämer
Mark Levis
Giovanni Martinelli
Alexander Perl
Nigel Russell
Malaz Abutarif
Youngsook Choi
Ophelia Yin
机构：
[1] Daiichi Sankyo,Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V
[2] Inc,Division of Hematology and Oncology, Abramson Cancer Center
[3] Cognigen Corporation,Centre for Clinical Haematology
[4] a Simulations Plus Company,undefined
[5] Georgia Cancer Center at Augusta University,undefined
[6] University of Kansas Cancer Center,undefined
[7] City of Hope,undefined
[8] University of Heidelberg,undefined
[9] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,undefined
[10] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS,undefined
[11] University of Pennsylvania,undefined
[12] Nottingham University Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2021年 / 87卷
关键词：
Concentration–QTc analysis; Quizartinib; AC886; Relapsed/refractory; Acute myeloid leukemia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：513 / 523
页数：10
相关论文
共 50 条
  • [1] Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
    Kang, Dongwoo
    Ludwig, Elizabeth
    Jaworowicz, David
    Huang, Hannah
    Fiedler-Kelly, Jill
    Cortes, Jorge
    Ganguly, Siddhartha
    Khaled, Samer
    Kraemer, Alwin
    Levis, Mark
    Martinelli, Giovanni
    Perl, Alexander
    Russell, Nigel
    Abutarif, Malaz
    Choi, Youngsook
    Yin, Ophelia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (04) : 513 - 523
  • [2] Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
    Kang, Dongwoo
    Ludwig, Elizabeth
    Jaworowicz, David
    Huang, Hannah
    Fiedler-Kelly, Jill
    Cortes, Jorge
    Ganguly, Siddhartha
    Khaled, Samer
    Kraemer, Alwin
    Levis, Mark
    Martinelli, Giovanni
    Perl, Alexander
    Russell, Nigel
    Abutarif, Malaz
    Choi, Youngsook
    Mendell, Jeanne
    Yin, Ophelia
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (12): : 1629 - 1641
  • [3] Pooled Safety Analysis of Quizartinib Monotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Kraemer, Alwin
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Russell, Nigel H.
    Choi, Youngsook
    Mendell, Jeanne
    Namuyinga, Ruth
    Hoang Pham
    Said, Nabil
    Wang, Yibin
    Mitov, Tsvetomir
    Kim, Ben
    Khaled, Samer K.
    BLOOD, 2019, 134
  • [4] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
    Kensuke Usuki
    Hiroshi Handa
    Ilseung Choi
    Takahiro Yamauchi
    Hiroatsu Iida
    Tomoko Hata
    Shoichi Ohwada
    Noriko Okudaira
    Kota Nakamura
    Sakura Sakajiri
    International Journal of Hematology, 2019, 110 : 654 - 664
  • [5] Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study
    Usuki, Kensuke
    Handa, Hiroshi
    Choi, Ilseung
    Yamauchi, Takahiro
    Iida, Hiroatsu
    Hata, Tomoko
    Ohwada, Shoichi
    Okudaira, Noriko
    Nakamura, Kota
    Sakajiri, Sakura
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (06) : 654 - 664
  • [6] Concentration-QT Analysis of Quizartinib in Patients with Relapsed/Refractory AML
    Kang, Dongwoo
    Lin, Kuan-ju
    Ludwig, Elizabeth
    Yin, Ophelia
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S23 - S24
  • [7] Data from French named patient program of quizartinib in relapsed/refractory acute myeloid leukemia
    Fodil, S.
    Raffoux, E.
    Dumas, P. Y.
    Desbrosses, Y.
    Larosa, F.
    Chantepie, S.
    Larcher, M. V.
    Mear, J. B.
    Peterlin, P.
    Hunault-Berger, M.
    Hospital, M. A.
    Morel, V.
    Lucas, N.
    Vidal, V.
    Salanoubat, C.
    Michel, J.
    Mediavilla, C.
    Ojeda-Uribe, M.
    Alexis, M.
    Frayfer, J.
    Carre, M.
    Maillard, N.
    Redjoul, R.
    Banos, A.
    Detrait, M.
    Cluzeau, T.
    Wickenhauser, S.
    Chaoui, D.
    Elassy, M.
    Pigneux, A.
    Dombret, H.
    Recher, C.
    Bertoli, S.
    LEUKEMIA & LYMPHOMA, 2021, 62 (07) : 1756 - 1760
  • [8] Outcome of Refractory and Relapsed Patients with Acute Myeloid Leukemia
    Niederwieser, Dietger
    Krahl, Rainer
    Kahle, Christoph
    Scholl, Sebastian
    Wolf, Hans-Heinrich
    Cross, Michael
    Hegenbart, Ute
    Peter, Norma
    Niederwieser, Christian
    Florschuetz, Axel
    Reifenrath, Kolja F. B.
    Zojer, Niklas
    Junghanss, Christian
    Sayer, Herbert
    Schmidt, Volker
    Maschmeyer, Georg
    Hochhaus, Andreas
    Fischer, Thomas
    Al-Ali, Haifa Kathrin
    Heinicke, Thomas
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 106 - 106
  • [9] Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia
    Perl, Alexander E.
    Lu, Qiaoyang
    Fan, Alan
    Hasabou, Nahla
    Berrak, Erhan
    Tiu, Ramon V.
    BLOOD, 2020, 136
  • [10] Progress and strategies for patients with relapsed and refractory acute myeloid leukemia
    Litzow, Mark R.
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 130 - 137
12345